Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

595.68
+3.690.62%
Post-market: 598.032.30+0.39%19:53 EDT
Volume:904.97K
Turnover:539.22M
Market Cap:63.13B
PE:15.01
High:600.75
Open:593.00
Low:588.67
Close:591.99
52wk High:1,154.56
52wk Low:476.49
Shares:105.99M
Float Shares:103.30M
Volume Ratio:0.75
T/O Rate:0.88%
Dividend:2.64
Dividend Rate:0.44%
EPS(TTM):39.67
EPS(LYR):40.90
ROE:15.34%
ROA:6.66%
PB:2.11
PE(LYR):14.57

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Sep 12

BRIEF-Libtayo Plus Chemotherapy Results At Five Years Reinforce Significant And Durable Improvements In Survival

Reuters
·
Sep 09

Regeneron Announces Promising Five-Year Results for Libtayo in Advanced Non-Small Cell Lung Cancer, Doubling Overall Survival Rates

Reuters
·
Sep 09

Regeneron Pharmaceuticals Inc - Libtayo Plus Chemotherapy Shows 19.4% Five-Year Survival Rate

THOMSON REUTERS
·
Sep 09

Libtayo® (Cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 09

Swiss stocks - Factors to watch on September 9

Reuters
·
Sep 09

Sandoz Group AG Resolves Patent Litigation with Regeneron, Paving the Way for US Launch of Aflibercept Biosimilar

Reuters
·
Sep 09

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Sep 09

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-09-08

Reuters
·
Sep 08

BRIEF-Regeneron Advances Allergy Pipeline With Two Positive Phase 3 Trials Evaluating Antibody-Blockers

Reuters
·
Sep 08

Regeneron Pharmaceuticals Announces Positive Phase 3 Trial Results for Cat and Birch Allergy Antibody Blockers

Reuters
·
Sep 08

Regeneron Advances Allergy Pipeline With Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

THOMSON REUTERS
·
Sep 08

Regeneron Pharmaceuticals Inc - Both Trials Met Primary and Secondary Endpoints

THOMSON REUTERS
·
Sep 08

Regeneron Pharmaceuticals Inc - Additional Phase 3 Development Is Planned to Begin in First Half of 2026

THOMSON REUTERS
·
Sep 08

Regeneron Pharmaceuticals Inc - Combination Therapy Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Sep 08

Sanofi's Weak Data on New Drug Adds to Vaccine Challenges -- Market Talk

Dow Jones
·
Sep 08

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Sep 06

Regeneron Pharmaceuticals Inc. to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Reuters
·
Sep 05

Sanofi Unveils Promising Phase 2a Results for Brivekimig in Treating Moderate-to-Severe Hidradenitis Suppurativa at EADV Congress

Reuters
·
Sep 04

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Sep 04